MGN1703 Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at

Share Article adds “MGN1703 (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store. This report focuses on the current treatment landscape, unmet needs, current pipeline and commercial opportunities in the colorectal cancer market.

MGN1703 Colorectal Cancer Treatment Market

MGN1703 Colorectal Cancer Treatment Market

The report “MGN1703 (Colorectal Cancer) – Forecast and Market Analysis to 2023” focuses on the current treatment landscape, unmet needs, current pipeline and commercial opportunities in the colorectal cancer market. Mologen AG is developing MGN1703 as a maintenance therapy for the treatment of advanced CRC patients with disease control after first-line induction chemotherapy treatment with or without biological treatment. The developer launched the pivotal Phase III IMPALA European trial to evaluate this drug in September 2014. This randomized, multicenter, open-label trial is investigating MGN1703 as a monotherapy compared to investigator choice maintenance treatment, namely treatment break, reduced treatment, and continued treatment, and is due to begin enrollment of an estimated total 540 patients in August 2014. Complete Report is Available @ .

MGN1703 is synthetic DNA-based immunomodulato prescribed for the treatment of metastatic colorectal cancer. The drug is aids patients to recover from chemotherapy sessions and it also boost the immune system. The drug acts as toll-like receptor 9 agonist. Side effects of the drug include fatigue, fever, atypical muscle ache, rash and paresthesia.

Reasons to Buy

  •     Understand and capitalize by identifying products that are most likely to ensure a robust return
  •     Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
  •     Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  •     Make more informed business decisions from insightful and in-depth analysis of MGN1703 performance
  •     Obtain sales forecast for MGN1703 from 2013-2023 in top five countries (France, Germany, Italy, Spain and the UK)

Order a Purchase copy of report @ .

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports

3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Clinical Staging
3.3 Symptoms

4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Screening and Diagnosis
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice

5 Competitive Assessment
5.1 Overview

6 Unmet Need and Opportunity
6.1 Overview
6.2 Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity

7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development

8 MGN1703
8.1 Overview
8.2 Efficacy
8.3 Safety
8.4 Dosing and Formulation
8.5 Potential Clinical and Commercial Positioning
8.6 SWOT Analysis
8.7 Forecast

9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Colorectal Cancer Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 General Pricing Assumptions
9.4.4 Average Body Weight and Surface Area Across the 8MM
9.4.5 Generic Erosion
9.4.6 Pricing of Pipeline Agents
9.5 Primary Research - KOLs Interviewed for this Report
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Analyst
9.7.2 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer

List of Tables
Table 1: TNM and Staging Classification System for CRC
Table 2: Symptoms of Colorectal Cancer
Table 3: Treatment Guidelines for CRC
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013
Table 6: Leading Treatments for CRC, 2014
Table 7: Unmet Need and Opportunity in CRC
Table 8: Product Profile - MGN1703
Table 9: MGN1703 SWOT Analysis, 2014
Table 10: Global Sales Forecasts ($m) for MGN1703, 2013-2023
Table 11: Average Body Weight and Surface Area Across the 8MM
Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: CRC - Phase III Pipeline
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in CRC, 2013-2023
Figure 3: Clinical and Commercial Positioning of MGN1703

Explore more reports on Cancer Drugs industry at .

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
Follow >
Sandler Research
since: 04/2014
Like >
Follow us on
Visit website